Vinorelbine alternating oral and intravenous plus carboplatin in advanced non-small-cell lung cancer: Results of a multicentre phase II study

Annals of Oncology

Volumn 15, Issue 6, 2004, Pages 921-927

  O'Brien, Maryo E R ^a,i   Szczesna, A ^b   Karnicka, H ^c   Zatloukal, P ^d   Eisen, T ^e   Hartmann, W ^f   Kasan, P ^g   Longerey, B ^h   Lefresne, F ^h  

^a Royal Marsden Hospital   (United Kingdom)

^b Regional Lung Diseases Hospital   (Poland)

^c PCK Maritime Hospital   (Poland)

^d UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

^e NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

^f Central Hospital   (Germany)

^g National Oncology Institute   (Slovakia)

^h INSTITUT DE RECHERCHE PIERRE FABRE   (France)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Chemotheraphy; Non small cell lung cancer; Oral vinorelbine

Indexed keywords

CARBOPLATIN; METOCLOPRAMIDE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; BODY WEIGHT DISORDER; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DOSE RESPONSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METASTASIS POTENTIAL; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SENSORY DYSFUNCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LOCALIZATION; WEIGHT REDUCTION;

EID: 3442901973     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh233     Document Type: Article

References (27)

1. Jemal A, Thomas A, Murray T et al. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small cell lung cancer. J Clin Oncol 2004; 22: 330-353.
3. Manegold C. Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer 2001; 34 (Suppl 2): S165-S170.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-98.
5. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933-937.
6. Liu G, Franssen E, Fitch ML et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-115.
7. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 2001;12:1643-1649.
8. Jassem J, Ramlau R, Karnicka-Mlodkowska H et al. A multicenter randomized phase II study of oral vs intravenous vinorelbine in advanced non-small cell lung cancer patients. Ann Oncol 2001; 12: 1375-1381.
9. Gridelli C, Parlier Y, Brandely M et al. Oral chemotherapy and upper gastro-intestinal tolerance (UGT) improvement of nausea and vomiting in non-small cell lung cancer (NSCLC) patients (pts) treated with oral navelbine (NVB) and standard antiemetic prophylaxis. Eur J Cancer 2003; 1: (Abstr 801).
10. Jacoulet P, Breton JL, Westeel V et al. Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer. Lung Cancer 1995; 12: 247-257.
11. Colleoni M, Boni L, Vicario G et al. A dose escalating study of carboplatin combined with vinorelbine in non-small cell lung cancer. Oncology 1996; 53: 364-368.
12. Parente B, Barat F, Moura E et al. Chemotherapy with vinorelbine (Navelbine: NVB) + carboplatin in advanced non-small cell lung cancer (NSCLC). Eur J Cancer 1997; 33 (Suppl 8): (Abstr 1089).
13. Lena H, Pelletier A, Lefeuvre C et al. Essai de phase II de traitement des CBNPC stade IV par l'association carboplatine-navelbine. Rev Mal Respir 1999; 16: (Abstr 140).
14. Vincent M, Rorke S, Tomiak A et al. Carnavel retrospective experience with combination vinorelbine (VLB) and carboplatinum in 35 patients with stage III/IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2000; 19: (Abstr 2109).
15. Bueltzingsloewen F. Vinorelbine (VNR) and carboplatinum (CAR) in patients with stage III B/IV non-small cell lung cancer (NSCLC). Ann Oncol 2000; 11: (Abstr 5438).
16. Couture F, Vincent MD, Couture F et al. Carboplatin and vinorelbine ("Carnavel"): a prospective phase II evaluation of 2 doses of carboplatin in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: 675 (Abstr 2715).
17. Baekke J, Sindrup H, Olesen R et al. Survival in advanced NSCLC and pretreatment characteristics predicting outcome of chemotherapy in patients treated with carboplatin and vinorelbine. Lung Cancer 2003; 41 (Suppl 2): 12.
18. Maquire J, Smith N, Kelly V et al. Carboplatin and vinorelbine as first line chemotherapy in NSCLC. Lung Cancer 2003; 41 (Suppl 2): 31.
19. Jassem J, Kosmidis P, Ramlau R et al. Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small cell lung cancer. Ann Oncol 2003; 14: 1634-1639.
20. Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-151.
21. World Health Organization. WHO Handbook for Reporting Results in Cancer Treatment. Geneva, Switzerland: WHO 1979.
22. Therasse P, Arbuck SG, Eisenhauer EH et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
23. Calvert AH. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol 1982; 9: 140-147.
24. Partridge AH, Avoin J, Wang SP, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652-661.
25. Wozniak AJ, Crowley JJ, Balcerzak et al. Randomized trial comparing cisplatin with cisplatin versus cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-2465.
26. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001; 13: 3210-3218.
27. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317: 771-775.